Sanofi Video Q&A: CEO Chris Viehbacher Comments on Key Messages from the Investor Relations Seminar

PARIS--(BUSINESS WIRE)-- Sanofi, a global and diversified healthcare leader, held its annual Investor Relations Thematic Seminar, focused this year on the group's strategy and outlook. CEO Chris Viehbacher comments on the key messages to investors.

Click to watch the video:
http://www.eurobusinessmedia.com/Sanofi-video-Q-A-CEO-Chris-Viehbacher-comments-on-key-messages-from-the-Investor-Relations-Seminar?utm_source=ceo-direct&utm_medium=bw

Topics covered in the interview include:

  • Industry resilience
  • Company transformation
  • Growth platforms
  • Genzyme
  • Innovative products
  • Guidance for 2012-2015
  • Shareholder return

About Sanofi:

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Company website: www.sanofi.com



CONTACT:

SANOFI
Investor Relations:
Sébastien Martel
[email protected]
+33 1 53 77 45 45
or
Media Relations:
[email protected]
+33 (0)1 53 77 45 02

KEYWORDS:   United States  Europe  North America  France  New York

INDUSTRY KEYWORDS:   Health  Communications  Public Relations/Investor Relations  Diabetes  Medical Supplies

MEDIA:

Logo
 Logo

Suggested Articles

BMS' Opdivo-Yervoy combo is playing in an increasingly crowded space. But the company is leaning on new long-term data to set its regimen apart.

GSK and Alcon have pulled off prescription-to-OTC switches in hopes of giving aging brands Voltaren and Pataday a boost.

Sanofi didn't hesitate to enter Zika vaccine R&D, and despite the associated scandal, the company is again jumping into emerging disease vaccine R…